BOSTON, May 07, 2018 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference call and webcast on Thursday, May 10, 2018 at 8:00 a.m. ET to discuss its first quarter 2018 financial results and provide a business update.
To participate in the conference call, please dial (888) 584-2172, (774) 264-7578 (international) and refer to conference ID: 4076397. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine. For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact:
Amy Sullivan
SVP, Corporate Affairs
T: 617-466-3519
[email protected]


Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 



